| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-07 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.24 | 2e-05 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.23 | 3e-05 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-05 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.14 | 3e-05 |